| [1] |
Wallace ZS, Naden RP, Chari S, et al. The 2019 American College of Rheumatology/European League Against Rheumatism classification criteria for IgG4-related disease [J]. Ann Rheum Dis, 2020, 79(1): 77-87.
|
| [2] |
Perugino CA, Stone JH. IgG4-related disease: an update on pathophysiology and implications for clinical care [J]. Nat Rev Rheumatol, 2020, 16(12): 702-714.
|
| [3] |
Lian L, Wang C, Tian JL. IgG4-related retroperitoneal fibrosis: a newly characterized disease [J]. Int J Rheum Dis, 2016, 19(11): 1049-1055.
|
| [4] |
Raglianti V, Rossi GM, Vaglio A. Idiopathic retroperitoneal fibrosis: an update for nephrologists [J]. Nephrol Dial Transplant, 2021, 36(10): 1773-1781.
|
| [5] |
Vaglio A, Salvarani C, Buzio C. Retroperitoneal fibrosis [J]. Lancet, 2006, 367(9506): 241-251.
|
| [6] |
Sasaki T, Akiyama M, Kaneko Y, et al. Risk factors of relapse following glucocorticoid tapering in IgG4-related disease [J]. Clin Exp Rheumatol, 2018, 36 Suppl 112(3): 186-189.
|
| [7] |
Khosroshahi A, Wallace ZS, Crowe JL, et al. International consensus guidance statement on the management and treatment of IgG4-related disease [J]. Arthritis Rheumatol, 2015, 67(7): 1688-1699.
|
| [8] |
Kamisawa T, Okazaki K, Kawa S, et al. Amendment of the Japanese consensus guidelines for autoimmune pancreatitis, 2013 III. Treatment and prognosis of autoimmune pancreatitis [J]. J Gastroenterol, 2014, 49(6): 961-970.
|
| [9] |
Hart PA, Kamisawa T, Brugge WR, et al. Long-term outcomes of autoimmune pancreatitis: a multicentre, international analysis [J]. Gut, 2013, 62(12): 1771-1776.
|
| [10] |
Mahajan VS, Mattoo H, Deshpande V, et al. IgG4-related disease [J]. Ann Rev Pathol, 2014, 9: 315-347.
|
| [11] |
Lanzillotta M, Fernàndez-codina A, Culver E, et al. Emerging therapy options for IgG4-related disease [J]. Expert Rev Clin Immunol, 2021, 17(5): 471-483.
|
| [12] |
Omar D, Chen Y, Cong Y, et al. Glucocorticoids and steroid sparing medications monotherapies or in combination for IgG4-RD: a systematic review and network meta-analysis [J]. Rheumatology (Oxford), 2020, 59(4): 718-726.
|
| [13] |
Nikiphorou E, Galloway J, Fragoulis GE. Overview of IgG4-related aortitis and periaortitis. a decade since their first description [J]. Autoimmun Rev, 2020, 19(12): 102694.
|
| [14] |
Khosroshahi A, Carruthers MN, Stone JH, et al. Rethinking Ormond′s disease: "idiopathic" retroperitoneal fibrosis in the era of IgG4-related disease [J]. Medicine (Baltimore), 2013, 92(2): 82-91.
|
| [15] |
张文，董凌莉，朱剑，等. IgG4相关性疾病诊治中国专家共识[J]. 中华内科杂志，2021, 60(3): 192-206.
|
| [16] |
Wallwork R, Wallace Z, Perugino C, et al. Rituximab for idiopathic and IgG4-related retroperitoneal fibrosis [J]. Medicine (Baltimore), 2018, 97(42): e12631.
|
| [17] |
Wang Y, Guan Z, Gao D, et al. The value of 18F-FDG PET/CT in the distinction between retroperitoneal fibrosis and its malignant mimics [J]. Semin Arthritis Rheum, 2018, 47(4): 593-600.
|
| [18] |
Morin G, Mageau A, Benali K, et al. Persistent FDG/PET CT uptake in idiopathic retroperitoneal fibrosis helps identifying patients at a higher risk for relapse [J]. Eur J Intern Med, 2019, 62: 67-71.
|
| [19] |
Wallace ZS, Mattoo H, Carruthers M, et al. Plasmablasts as a biomarker for IgG4-related disease, independent of serum IgG4 concentrations [J]. Ann Rheum Dis, 2015, 74(1): 190-195.
|
| [20] |
Mattoo H, Mahajan VS, Della-Torre E, et al. De novo oligoclonal expansions of circulating plasmablasts in active and relapsing IgG4-related disease [J]. J Allergy Clin Immunol, 2014, 134(3): 679-687.
|
| [21] |
Sakamoto A, Ishizaka N, Imai Y, et al. Serum levels of IgG4 and soluble interleukin-2 receptor in patients with abdominal and thoracic aortic aneurysm who undergo coronary angiography [J]. Atherosclerosis, 2012, 221(2): 602-603.
|
| [22] |
Lanzillotta M, Campochiaro C, Mancuso G, et al. Clinical phenotypes of IgG4-related disease reflect different prognostic outcomes [J]. Rheumatology (Oxford), 2020, 59(9): 2435-2442.
|
| [23] |
Wallace ZS, Zhang Y, Perugino CA, et al. Clinical phenotypes of IgG4-related disease: an analysis of two international cross-sectional cohorts [J]. Ann Rheum Dis, 2019, 78(3): 406-412.
|
| [24] |
Khosroshahi A, Carruthers MN, Deshpande V, et al. Rituximab for the treatment of IgG4-related disease: lessons from 10 consecutive patients [J]. Medicine (Baltimore), 2012, 91(1): 57-66.
|
| [25] |
Perugino CA, Stone JH. IgG4-related disease: an update on pathophysiology and implications for clinical care [J]. Nat Rev Rheumtol, 2020, 16(12): 702-714.
|
| [26] |
Lanzillotta M, Stone JH, Della-Torre E. B-cell depletion therapy in IgG4-related disease: state of the art and future perspectives [J]. Mod Rheumatol, 2023, 33(2): 258-265.
|
| [27] |
Quattrocchio G, Barreca A, Demarchi A, et al. Long-term effects of intensive B cell depletion therapy in severe cases of IgG4-related disease with renal involvement [J]. Immunol Res, 2020, 68(6): 340-352.
|
| [28] |
Lanzillotta M, Della-Torre E, Wallace ZS, et al. Efficacy and safety of rituximab for IgG4-related pancreato-biliary disease: a systematic review and meta-analysis [J]. Pancreatology, 2021, 21(7): 1395-1401.
|
| [29] |
Hamdan A, Moeen Z, Tariq H, et al. An interesting case of immunoglobulin G4-related retroperitoneal fibrosis treated with rituximab [J]. Cureus, 2021, 13(9): e17940.
|
| [30] |
Ebbo M, Grados A, Samson M, et al. Long-term efficacy and safety of rituximab in IgG4-related disease: data from a French nationwide study of thirty-three patients [J]. PLoS One, 2017, 12(9): e0183844.
|
| [31] |
Carruthers MN, Topazian MD, Khosroshahi A, et al. Rituximab for IgG4-related disease: a prospective, open-label trial [J]. Ann Rheum Dis, 2015, 74(6): 1171-1177.
|
| [32] |
Boyeva V, Alabsi H, Seidman MA, et al. Use of rituximab in idiopathic retroperitoneal fibrosis [J]. BMC Rheumatol, 2020, 4: 40.
|
| [33] |
Almeqdadi M, Al-Dulaimi M, Perepletchikov A, et al. Rituximab for retroperitoneal fibrosis due to IgG4-related disease: a case report and literature review [J]. Clin Nephrol Case Stud, 2018, 6: 4-10.
|
| [34] |
Dong L, Cong Y, Chen Y, et al. Glucocorticoids and steroid sparing medications monotherapies or in combination for IgG4-RD: a systematic review and network meta-analysis [J]. Rheumatology (Oxford), 2020, 59(4): 718-726.
|